• Claude Linassier, Delphine Carmier, Pierre Combe, Benjamin Faivre D'Arcier, Franck Bruyere, and Berangere Narciso.
• Centre Hospitalier Universitaire Bretonneau, Centre Henry S. Kaplan, Department for Oncology, 2 Boulevard Tonnelle, 37044 Tours Cedex 9, France. linassier@med.univ-tours.fr
• Anticancer Res. 2012 Feb 1; 32 (2): 697-700.

AbstractSix targeted agents [sorafenib, sunitinib, temsirolimus, bevacizumab (plus interferon), everolimus and pazopanib] have been approved for the treatment of patients with metastatic renal cell carcinoma. As disease progression is inevitable, most patients will receive several lines of treatment. However, the choice regarding which sequence of drugs to use remains unclear, particularly concerning the drug class, i.e. those targeting the vascular endothelial growth factor (receptor) [VEGF(R)] pathway versus those acting on the mammalian target of rapamycin pathway. There appears to be no absolute crossresistance between tyrosine kinase inhibitors (TKIs) acting on the VEGF(R) pathway, and there have been numerous reports of two TKIs being successfully used in sequence. We report the case of a 63-year-old woman who responded for 24 months to three successive lines of treatment with different TKIs (sunitinib, axitinib and sorafenib). This suggests that TKIs targeting VEGFR should be considered as individual drugs and not as a single class.

36 keywords...

hide…